Pfizer desperately needs ammunition in its fight against activist investor Starboard Value. Fortunately for chief executive Albert Bourla, it found some by way of better than expected third-quarter results. An unexpectedly large surge of Covid-19 infections over the summer helped boost sales of its medicines Paxlovid and Comirnaty and allowed Pfizer to raise its outlook for full-year sales and adjusted earnings.
辉瑞(Pfizer)在与维权投资者Starboard Value的斗争中急需弹药。幸运的是，好于预期的第三季度业绩给首席执行官艾伯乐(Albert Bourla)提供了一些。今年夏天，新冠感染病例出乎意料地大幅增加，促进了辉瑞Paxlovid和Comirnaty药物的销售，使其上调了全年销售额和调整后利润的预期。
您已阅读16%（572字），剩余84%（2930字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。